Vaxigrip clinical trials

Studies by the year they started

18 studies that test it; most in 2007 (3)

Who runs them

Industry 5 · Other 13

Sanofi Pasteur, a Sanofi Company (5) · PATH (2) · Medical University of Warsaw (1) · University of Maryland, Baltimore (1) · Research Institute for Biological Safety Problems (1) · National University Hospital, Singapore (1) · Brenda Coleman (1) · Center for Disease Prevention and Control of Beijing Military Region (1)

Often tested with

Tested in the same studies.

Influenza Vaccines (4) · Poliovirus Vaccine, Inactivated (1)

Studies

Open first, then newest update. How each study uses vaxigrip is read from its arms, and is right about nine times in ten.

Testing it · 18

• Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza VaccinationRecruitingPhase 3University of BrawijayaNCT07604103Written as Vaxigrip
• Effectiveness and Tolerability of Influenza Vaccine in Patients at Risk for Severe and Complicated InfluenzaActive, not recruitingPhase 4Medical University of WarsawNCT06286488Written as Vaxigrip
• Maternal Flu Vaccine Trial in Bamako, MaliCompletedPhase 4University of Maryland, BaltimoreNCT01430689Written as Inactivated Influenza Vaccine Trivalent Types A and B
• Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in KoreaCompletedPhase 4Sanofi Pasteur, a Sanofi CompanyNCT01215669Written as Vaxigrip®: Split virion inactivated influenza vaccine
• Immunogenicity and Safety Study of Allantoic Split Inactivated Seasonal Influenza Vaccine (VSI)CompletedPhase 2Research Institute for Biological Safety ProblemsNCT03016143Written as VAXIGRIP
• The Immune Response to Influenza Vaccinations in Elderly IndividualsCompletedPhase 4National University Hospital, SingaporeNCT03266237Written as Vaxigrip®
• A Time-motion Study Comparing Self- to Nurse-vaccination With Influenza VaccineCompletedPhase 4Brenda ColemanNCT01665807Written as Vaxigrip
• Safety and Immunogenicity of Three Seasonal Trivalent Influenza Vaccines in China MilitaryCompletedPhase 4Center for Disease Prevention and Control of Beijing Military RegionNCT02640989Written as Seasonal trivalent influenza vaccine, VAXIGRIP
• Study of Immune Response in Adults and Elderly Subjects Vaccinated With Inactivated Influenza VaccinesCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT00776438Written as Inactivated, split-virion, influenza vaccine
• Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Lung Transplant RecipientsCompletedNot applicableUniversity of AlbertaNCT00760175Written as Vaxigrip (Aventis-Pasteur Canada)
• Comparison of 4 Influenza Vaccines in SeniorsCompletedPhase 4University of British ColumbiaNCT01368796Written as Vaxigrip
• Differences in Response to the Flu Vaccine Among Adults With HIV and Without HIV in UgandaCompletedNot applicableEmory UniversityNCT01916759Written as Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)
• A Study of the Immunogenicity and Safety of the 2007-2008 Influenza VaccineCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT00491257Written as Inactivated influenza vaccine (split virion) NH 2007-2008 formulation
• Lot-to-Lot Consistency Study of the Investigational, Inactivated, Split-Virion Influenza Vaccine in AdultsCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT00383539Written as Inactivated Split-virion influenza vaccine
• Immunogenicity of the Inactivated Split-Virion Influenza Vaccine in Renal Transplant SubjectsCompletedPhase 2Sanofi Pasteur, a Sanofi CompanyNCT00606359Written as Inactivated, split-virion influenza virus
• Immunogenicity and Safety Trial of Adjuvanted and Non-adjuvanted Trivalent Influenza Vaccine in Tropical AfricaCompletedPhase 2PATHNCT01819155Written as Seasonal trivalent inactivated influenza vaccine
• Inactivated Influenza Vaccine Effectiveness in Tropical AfricaCompletedPhase 4PATHNCT00893906Written as seasonal trivalent inactivated influenza vaccine
• Influenza Vaccine Dose-Response in Infants and Toddlers: Immunogenicity and ReactogenicityCompletedPhase 3British Columbia Centre for Disease ControlNCT00710866Written as Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)